Sabiha Essack is the South African Research Chair (SARChI) in Antibiotic Resistance and One Health and Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal (UKZN).  She is also the Vice Chair of the WHO Strategic and Technical Advisory Group for Antimicrobial Resistance (STAG-AMR), Senior Implementation Research Advisor at the International Centre for Antimicrobial Resistance Solutions (ICARS) in Denmark, member of the Scientific Advisory Board of the Joint Programming Initiative on AMR (JPIAMR) and member of the International Pharmacy Federation (FIP) AMR  Commission.  Professor Essack is chairperson of the Global Respiratory Infection Partnership (GRIP), she serves on the Advisory Board of the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the Fleming Fund Expert Advisory Group and is a member of the Wellcome Trust Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC).  Her research focuses on the molecular epidemiology of AMR using next generation sequencing and bioinformatics as well as One Health systems strengthening in the context of AMR.

Diane Flayhart is the Global Program Leader AMR at the Antimicrobial Resistance Fighter Coalition/BD in the United States. Diane leads efforts for the Antimicrobial Resistance Fighter Coalition, a global organization that aspires to change behaviors across the globe that will maintain the effectiveness of antibiotics for future generations. The Coalition seeks to substantially increase awareness of drug-resistant infections and encourage action across a wide range of stakeholders, including policymakers, health agency officials, professional societies, clinicians, patients, and family members. The Coalition is mobilized by BD. Diane has been with BD since 2007, serving in roles of increased responsibility focused on Marketing and Commercial Excellence. She started her career at Johns Hopkins Medical Institution working as a medical technologist in the Microbiology Laboratory. Diane completed my Master’s Degree in Business Administration at The Johns Hopkins University.

Yewande Alimi is the Antimicrobial Resistance (AMR) Program Coordinator at Africa Centres for Disease Control and Prevention, and co-lead for the Africa Union Task force on AMR. She co-chairs the Infection Prevention and Control (IPC) Section for COVID-19 response across the continent and provides technical IPC support to the Africa Task Force for Coronavirus. Dr Yewande is a trained Veterinary Surgeon and holds a Masters degree in Public Health (International Health) from the University of Nottingham in the United Kingdom. Drawing on a range of experience that includes veterinary medicine, public health policy and research, she currently leads the implementation of the Africa CDC Framework for AMR Control in Africa Union member states. She also leads on the One Health activities, development and implementation of one health programs within Africa CDC, across the African Union organizations and member states. Before joining the Africa CDC, Yewande practised as a Veterinary Surgeon in Nigeria. She worked as a research analyst at the Ludwig Boltzmann Institute of Health Technology Assessment, Austria and CompanDX, United Kingdom. She serves on several advisory boards and groups across the continent and globally. She is the One Health Technical Advisor for Global Emerging Pathogens Treatment Consortium. She is a member of the Scientific Task Force to Prevent Pandemics at the Source for the Harvard Global Health Institute (HGHI) and the Harvard T.H. Chan School of Public Health Center.

Bruce Altevogt is Vice President and Head External Medical Engagement within Pfizer Inc.’s Hospital Business Unit. In this role Dr. Altevogt is responsible for establishing and managing the business unit’s scientific and medical stakeholder engagement strategy. In addition, the External Medical Team supports the industry leading AMR surveillance program, ATLAS. Prior to this role he was a Senior Director of Science Policy and Science Advocacy within Global Policy and International Public Affairs. In this role Dr. Altevogt was responsible for managing policy issues in support of Pfizer’s research & development enterprise, vaccines and was lead for anti-microbial resistance policy. Dr. Altevogt serves as the Board Chair of Healthcare Ready, a non-profit organization that helps to strengthen healthcare supply chains by addressing pressing issues before, during, and after disasters. In addition he serves a member of the AMR Alliance Board, an organization that measures and drives the life-sciences industry progress to curb antimicrobial resistance. Prior to joining Pfizer Inc. Dr. Altevogt served as a senior program officer on the Board on Health Sciences Policy at the Institute of Medicine (IOM). While at the IOM he led policy initiatives related to basic and translational research, drug discovery and development, and preparedness for catastrophic events. He oversaw the publication of over 50 IOM reports and directed multiple IOM studies. In his capacity at the IOM he served as director of the Forum on Medical and Public Health Preparedness for Catastrophic Events, the Forum on Neuroscience and Nervous System Disorders Forum, and number or additional activities. Dr. Altevogt received a doctorate from Harvard University’s Program in Neuroscience and a B.A. from the University of Virginia, where he majored in Biology and minored in South Asian Studies. He is a published author of multiple scientific articles.

Jean-Louis Tissier is Vice President, Public and Government Affairs – AMR at bioMérieux In charge of implementing a Public Relations strategy focused on Antimicrobial Resistance (AMR) and Antimicrobial Stewardship (AMS), notably with respect to healthcare authorities, government bodies and trade associations, as well as with patient and healthcare professional associations. He joined the company 35 years ago holding roles of increasing responsibility, most recently as Vice President Global Marketing in Microbiology (2007-2011) and Vice President Northern Europe (2011-2019) which allowed him to accumulate rich experience in the field of in vitro diagnostics. Jean-Louis graduated from the Business School of the Conservatoire National Des Arts et Métiers in Paris and received his Master degree in Biology from the University of Paris.

Greg Frank is Director, Global Public Policy with MSD, where he leads global antimicrobial resistance (AMR) policy. Previously Dr. Frank served as Senior Director, Infectious Disease Policy at the Biotechnology Innovation Organization (BIO), where he led several infectious diseases policy issues, including AMR and vaccine regulatory policy. Prior to BIO, Dr. Frank led science and diagnostics policy as Program Officer for Science and Research policy at the Infectious Diseases Society of America (IDSA). Dr. Frank serves on the U.S. Presidential Advisory Committee on Antibiotic Resistant Bacteria (PACCARB), the Leadership Council of the National Institute of Antimicrobial Resistant Research and Education (NIAMREE), and the expert advisory committee for the Partnership to Fight Infectious Diseases. He has previously joined expert advisory committees of the Access to Medicines Foundation AMR Benchmark, the Global AMR R&D Hub, and the Duke-Margolis Center for Health Policy Antimicrobial Incentives & Payment Reform Project. He is also a Board member on the AMR Industry Alliance. Dr. Frank received his doctorate in immunology at the University of Pittsburgh and pursued his postdoctoral training at the Laboratory of Viral Diseases at the National Institute of Allergy & Infectious Diseases.

Senjuti Saha is a molecular microbiologist and an activist based in Bangladesh. She is currently the Director & Scientist at the Child Health Research Foundation, where she works at the intersection of microbiology and public health. After acquiring her PhD in Molecular Genetics at the University of Toronto in Canada, she moved to Bangladesh to work in the front lines of public health. Currently, she focuses on preventable pediatric infectious diseases, with the goal of using modern molecular technologies including on-site metagenomics to identify etiologies that evade standard laboratory testing. She has established genomic surveillance to track and understand the molecular basis of antimicrobial resistance in endemic bacterial pathogens. Her team also works to estimate the indirect impacts of vaccines on the overall health system of resource-constrained settings. Her work is grounded in advancing health and research equity – Senjuti believes that everyone across the world should have equal access to the practice and benefits of science.

Rony Zachariah, is a Scientist for Research for Implementation at the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and is the Coordinator of TDR's Structured Operational Research and Training Initiative (SORT IT). He holds a PhD in Operational Research and is one of the pioneers involved with the development of Operational research in health as a science. He has over 30 years of extensive professional experience working in various medical and coordination capacities in Nigeria, Chad, Kenya, Somalia, Liberia, Malawi, Sri-Lanka, Afghanistan, Tajikistan, Rwanda, Lebanon, and in Europe. He previously served as the Director of Operations research at Médecins Sans Frontières (MSF) and as strategic advisor on operations to the MSF Director General in Brussels. He has also contributed as Consultant to European Association for Development and Health.

Robert Terry is the Manager of Research Policy at the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), where he is responsible for knowledge management, open access, data sharing and ensuring evidence is translated into policy and practice. Robert is a senior strategic and project manager with more than 25 years’ experience in strategy development and implementation. He holds a PhD in Global Health Research Policy and has previously worked at the Royal Society (the UK academy of science) where he ran the international research exchange programme and the Wellcome Trust where he was senior policy advisor leading the development of the Wellcome Trust’s first open access policy and the establishment of Europe PubMed Central. He has worked in various positions at WHO and has served as a consultant for Oxfam, United Nations Association International Service and UK Department For International Development in several African and Asian countries.

Mike Sharland is a leading expert in antimicrobial prescribing, resistance and healthcare associated infection in children. He is a Professor and Consultant in paediatric infectious diseases at St George's University Hospitals NHS Foundation Trust, UK. He is the lead clinical advisor for the neonatal and paediatric programme of the Global Antibiotic Research and Development Partnership (GARDP) and Vice-Chair and AMR lead of the Penta Foundation, a global Paediatric Infectious Diseases research network. He is the chief investigator for the Antimicrobial Resistance, Prescribing, and Consumption Data to Inform Country Antibiotic Guidance and Local Action (ADILA) project. He previously Chaired the UK Department of Health’s Expert Advisory Committee of Antimicrobial Prescribing, Resistance and Healthcare Associated Infection (APRHAI). He has been an advisor for the WHO for many years. He is member of the Expert Committee on the Selection and Use of Essential Medicines and Chair of the Antibiotic Working Group of the EML/EMLc, assisting with the development of the Access/Watch/Reserve (AWaRE) grouping of antibiotics and WHO global targets on use. 

Tine Rikke Jørgensen is a Consultant at the AMR Global Coordination Department at the WHO, HQ in Geneva and serves as the Senior Scientific Advisor at the International Centre for Antimicrobial Resistance Solutions (ICARS). A biologist with post-graduate training in Global Public Health and Health Economics, she has held various global positions in the public and private sector, specialized in access to medicines, health economics and policy as well as evaluation frameworks for introduction of new technologies. She has extensive experience in global public health leading governmental affairs, health advocacy and public affairs in vaccines and infectious diseases in international and national markets having worked at country level in China, Japan, US, Canada, Europe, Russia, Tanzania and Zanzibar, Kenya, Ethiopia, Uganda, Nepal, Bangladesh, India, Indonesia, Balkan region including Kosovo, Turkey, and the Russian Federation.

Aliya Naheed is the Head for the Initiative for Non-Communicable Diseases, Health System and Population Studies Division at the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b). Dr Naheed is a Medical doctor and public health researcher with extensive training in epidemiology, public health, behavioral intervention, health system and policy research. Strong background in disease surveillance, laboratory-based research, randomised control trial, experimental designs, case control study, longitudinal cohort, large scale nationwide surveys, qualitative study and economic evaluations. Current research interests primarily focus on prevention and control of non-communicable diseases through strengthening the local health systems.

Janet Midega is a Senior Research Advisor for Wellcome’s Drug Resistant Infections (DRI) programme where she is leading research activities within the priority program on DRI. She provides scientific leadership, program development and management support to the surveillance and epidemiology program on Antimicrobial Resistance (AMR) with a focus on determining the global burden of AMR. She also leads science and policy research which aims at evaluating how legislative changes banning antibiotic use in animal meat production can reduce the potential transfer of resistant pathogens between animals and humans; and a surveillance program on the development of a comprehensive data capture system for patient-centred AMR surveillance in low- and middle-income countries. In line with the DRI programmes interest in accelerating the development of new antibiotics, Janet worked closely with CARB-x based at Boston University, USA to support the discovery and development of novel antibiotics, as part of Wellcome’s role as an accelerator and support for companies joining CARBx. Prior to joining Wellcome, Janet was a scientist at Imperial College and the University of Oxford, Big Data Institute; in collaboration with the KEMRI- Wellcome Trust Research Programme for over 10 years conducting academic research on the biology of disease vectors and the genomic epidemiology of malaria. Janet is also a Senior Fellow in Public Health at the Aspen Institute, Washington DC, USA.

Dr Dilruba Ahmed is a Clinical Microbiologist who is currently the Head of Clinical Microbiology and Immunology at icddr,b. She has been involved in the field diagnostic microbiology and immunology for over a decade.  Dr Ahmed, along with a team of skilled and dedicated laboratory staff, provides excellent service to users through its modern and cutting edge equipment. Under her guidance the laboratory has achieved international accreditation ISO 15189:2012 since 2010. The lab has an excellent platform to identify antibiotic resistance pattern since the 1990s.,To keep pace with the recent and actual therapeutic pattern, Dr Ahmed has updated her laboratory with modern automated facility for identification and antimicrobial resistance pattern. Along with supporting patient services, Dr Ahmed collaborated with both the internal and external researchers, supported research work and has published papers in peer reviewed journals. She hosts national and international for short term fellowship and also mentors MSc and PhD student. Dr Ahmed coordinated training and workshops for Laboratory Technologists and Microbiologists in Nepal and assessed The Clinical Laboratory and Public Health Laboratory at the National Referral Hospital to be the National Reference Laboratory.

Jose Procópio Moreno Senna, graduated in Pharmacy from the Federal University of Rio Grande do Sul (1987), a Master's degree in Microbiology, Pathogenesis of Microorganisms and Agents Antinfectieux - Université Paris Sud (1995), and Ph.D. in Cellular and Molecular Biology from the Federal University of Rio Grande do Sul 2001), post doc at Institut Pasteur, Unité des Agents Antibactériens 2003. He is currently a specialist in public health at the Institute of Immunobiological Technology - BioManguinhos - Fiocruz. He is a vice-coordinator of the Professional Master's Degree in Immunobiology Technology and a lecturer responsible for the discipline Bacteriology applied to Immunobiologics. He has experience in the field of Pharmacy, with emphasis on microbiology, working mainly on the following topics: multiresistant bacteria, development of passive immunotherapy - therapeutic monoclonal antibodies for the treatment of multiresistant bacteria, vaccines, and immunodiagnosis.

Ana Paula Carvalho-Assef -TBC

Silvia Bertagnolio is currently Unit Head in the Antimicrobial resistance (AMR) Division, at the World Health Organization (WHO) in Geneva. She leads its work around AMR evidence generation for policy development and laboratory strengthening. At WHO, she also leads the WHO Global Clinical Platform for COVID19, a global repository of anonymized clinical data of patients hospitalised for COVID-19 around the globe, that supports the generation of evidence based public health responses to COVID-19. Previous to this, Dr Silvia Bertagnolio led the HIV Drug Resistance (HIVDR) programme at the World Health Organization in Geneva. In that role, she was responsible for the development of global strategies and policies, including the Global Action Plan on HIVDR. She coordinated the Global WHO HIVDR Laboratory Network, and HIVDR surveillance programme in over 50 low- and middle-income countries. Dr. Bertagnolio is qualified as a medical doctor specialised in Infectious Diseases from the Catholic University, Rome. She holds an academic affiliation with UCL, London, as honorary senior research fellow. She has been Guest Editor of several journals, including Journal of Infectious Diseases and Clinical Infectious Diseases, and published over 100 peer-reviewed papers, and book chapters.